Compare Abbott Laboratories (ABT) vs Canadian Natural Resources Ltd. (CNQ) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Canadian Natural Resources Ltd. — how do they compare? Abbott Laboratories trades at $95.36 (market cap $166.94B), while Canadian Natural Resources Ltd. trades at $42.24 (market cap $84.83B). The key difference: Abbott Laboratories is the larger of the two by market cap, and Canadian Natural Resources Ltd. pays the higher dividend (4.32%). Which is the better fit depends on your goals.
| ABT | CNQ | |
|---|---|---|
Market Cap | $166.94B | $84.83B |
Sector | Health | Energy |
52-Week High | $136.62 | $50.55 |
52-Week Low | $82.57 | $29.31 |
Enterprise Value | $193.69B | $96.06B |
Dividend Yield | 2.63% | 4.32% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Canadian Natural Resources (CNQ) trades at $40.69, up 2.65% with strong earnings momentum after beating estimates for three consecutive quarters. The stock shows attractive valuation metrics with P/E of 11.8 and robust profitability including 24.5% net margin. Technical indicators signal bearish sentiment despite recent price strength, while analyst consensus remains overwhelmingly positive with 75% buy ratings. Recent dividend declarations and strong cash flow generation support shareholder returns.
CNQ presents a compelling value opportunity with solid fundamentals and positive earnings surprises, though technical weakness and oil price volatility pose near-term risks. The company's strong balance sheet and consistent dividend payments provide downside protection, while operational efficiency and production growth drive long-term potential. Investors should weigh valuation appeal against energy sector cyclicality and technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Canadian Natural Resources Ltd.
Canadian Natural Resources is one of the largest oil and natural gas producers in western Canada, supplemented by operations in the North Sea and Offshore Africa. The company's portfolio includes light and medium oil, heavy oil, bitumen, synthetic oil, natural gas liquids, and natural gas. Production averaged 1.16 million barrels of oil equivalent per day in 2020, and the company estimates that it holds over 11.5 billion boe of proven and probable crude oil and natural gas reserves.
Read more on CNQ →
